Contact Us

Value Evidence Communication

We believe that a credible value story requires a deep understanding of how ‘value’ is perceived by patients, providers, payers, and policymakers. It requires local knowledge of the product, care, and regulatory landscape.

At Excelra, we apply this understanding to package analytical insights into coherent and impactful global value dossiers, slide presentations and other market access collaterals, tailor-made to the intended target audience.

WEAVING A LUCID AND PERSUASIVE VALUE STORY

We believe that a credible value story requires a deep understanding of how ‘value’ is perceived by patients, providers, payers, and policymakers. It requires local knowledge of the product, standard of care (SoC) as per recommended treatment guidelines, therapy area and regulatory landscape.

The core value/reimbursement dossier includes a comprehensive repository of evidence supportive of the product value story, inclusive of the disease background, treatment guidelines, unmet needs, product information, burden of illness, clinical summaries, economic models, and indirect treatment comparisons for the intervention in the target population. At Excelra, we apply this understanding to package analytical insights for drugs and medical device appraisals into coherent and impactful value dossiers, slide presentations and other market access collaterals, tailor-made to the intended target audience, whether this is for health technology assessment (HTA) submissions (AMCP dossier, NICE submission dossier, CADTH submission dossier, etc.), internal stakeholders or other policy makers.

Typical problems we can solve for our partners

  • GVD creation to generate payer ready evidence
  • Development of value stories that are logical, supported with the best available data and designed collaboratively and iteratively with our clients throughout their asset life-cycle
  • Taking the clinical, economic and humanistic evidence and create effective, compelling value dossiers, stories, communication slides/decks and any necessary objection handling material
  • Supporting country specific submissions to communicate your assets value to country HTA or formulary submissions
  • Helping you to take the large volume of complex evidence and summarize it into effective value communication of your asset for your key stakeholders, whether internal or external payers/decision making bodies
  • Visualization of necessary materials to support internal/external stakeholder engagement on the assets value